Live Breaking News & Updates on Advance New Programs Targeting

Plan to Submit Application for Accelerated Approval for Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) in H1 2024Expects to Begin Enrollment in Phase 3 Confirmatory Trial, RAMP 301, of Avutometinib and Defactinib in LGSOC in Q4 2023Presented Additional Patient Subgroup Data for the. ....

United States , Ryan Porter , Elisa Buffington , Dan Paterson , Pancreatic Cancer Action Network Pan , Chugai Pharmaceutical Co Ltd , Development Collaboration , Foundation Inc , Drug Administration , Head Of Regulatory Affairs , Corporate Communications , Patient Impact , World Ovarian Cancer Coalition , Patient Impact Advisory Committee , International Conference On Molecular , Exchange Commission , European Network Of Gynaecological Oncological Trial , Ovarian Cancer Foundation , Raf And Mek Program , Submit Application , Accelerated Approval , Recurrent Low Grade Serous Ovarian Cancer , Begin Enrollment , Additional Patient Subgroup Data , Defactinib Showing Promising Levels , Prior Therapies Including After Poor Response ,